November 29, 2020

Market and Financial News Aggregator

Why is Gland Pharma citing India-China ties as key risk to IPO

1 min read



The pharma company that is majority-owned by Chinese conglomerate Fosun International has noted in its filings with Sebi that it could face supply disruptions in the future arising from the border confrontation that took place between India and China on June 20.



Source link

Leave a Reply